Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir combined with tocilizumab for COVID-19
ChiCTR2000030894Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of favipiravir and tocilizumab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Clinical cure rate. Started Mar 2020; status: recruiting.
02
Drugs
favipiravirtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030894.